← All trials
NCT03313557
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2017
- Primary completion
- Aug 16, 2019
- Completion date
- Aug 16, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 52
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Free University of AmsterdamOverall official - principal investigator
- AstraZenecaStudy director
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.